References 37327

References

1. Windler E, Zyriax BC. "Lifestyle changes for prevention of coronaryheart disease." Herz, 26, 8:513-22, 2001. http://link.springer.de/link/service/journals/00059/

2. Rasanen M et al. "Dietary patterns and nutrient intakes of 7-year-oldchildren taking part in an atherosclerosis prevention project in Finland." JAm Diet Assoc, 102, 4:518-24, 2002. www.eatright.org/journal

3. Bazzano LA et al. "Fruit and vegetable intake and risk ofcardiovascular disease in U.S. adults: the first National Health and NutritionExamination Survey Epidemiologic Follow-Up Study." Am J Clin Nutr,76, 1:93-99, 2002. www.ajcn.org

4. Fugh-Berman A. "Herbs and dietary supplements in the prevention andtreatment of cardiovascular disease." Prev Cardiol, 3, 1:24-32,2000. www.medscape.com/viewpublication/624_index

5. Giugliano D. "Dietary antioxidants for cardiovascularprevention." Nutr Metab Cardiovasc Dis, 10, 1:38-44, 2000. www.medikal.it/index_en.htm

6. Muntwyler J et al. "Vitamin supplement use in a low-risk populationof U.S. male physicians and subsequent cardiovascular mortality." ArchIntern Med, 162:1472-76, 2002. http://archinte.ama-assn.org

7. Heart Protection Study Collaborative Group. "MRC/BHF Heart ProtectionStudy of antioxidant vitamin supplementation in 20,536 high-risk individuals: arandomized placebo-controlled trial." Lancet, 360, 9326:23-33, 2002.www.thelancet.com

8. Salonen JT et al. "Antioxidant Supplementation in AtherosclerosisPrevention (ASAP) study: a randomized trial of the effect of vitamins E and C on3-year progression of carotid atherosclerosis." J Intern Med, 248,5:377-86, 2000. www.blackwell-synergy.com/servlet/useragent?func=showIssues&code=jim

9. Fang JC et al. "Effect of vitamins C and E on progression oftransplant associated arteriosclerosis: a randomized trial." Lancet,359, 9312:1108-13, 2002. www.thelancet.com

10. Mezzetti A et al. "Vitamin E and lipid peroxide plasma levelspredict the risk of cardiovascular events in a group of healthy very oldpeople." J Am Geriatr Soc, 49, 5:533-7, 2001. www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=jgs

11. Iannuzzi A et al. "Dietary and circulating antioxidant vitamins inrelation to carotid plaques in middle-aged women." Am J Clin Nutr,76, 3:582-7, 2002. www.ajcn.org

12. Kaikkonen J et al. "Supplementation with vitamin E but not withvitamin C lowers lipid peroxidation in vivo in mildly hypercholesterolemicmen." Free Rad Res, 35, 6:967-78, 2001. www.tandf.co.uk/journals

13. Hodis HN et al. "Alpha-tocopherol supplementation in healthyindividuals reduces low-density lipoprotein oxidation but not atherosclerosis:the Vitamin E Atherosclerosis Prevention Study (VEAPS)." Circulation,106, 12:1453-9, 2002. http://circ.ahajournals.org/

14. Blumberg JB. "An update: vitamin E supplementation and heartdisease." Nutr Clin Care, 5, 2:50-5, 2002. www.blackwell-science.com/~cgilib/bsinc.bin?Journal=clinical

15. Bunout D. "Therapeutic potential of vitamin E in heartdisease." Expert Opin Investig Drugs, 9, 11:2629-35, 2000. www.ashley-pub.com

16. Theriault A et al. "Tocotrienol: a review of its therapeuticlpotential." Clin Biochem, 32, 5:309-19, 1999. www.elsevier.nl/inca/publications/store/5/2/5/4/6/3

17. Sadeen T, Li D, Mehta JL. "Differntial effects of alpha- and gamma-tocopherolon low-density lipoprotein oxidation, superoxide activity, platelet aggregationand arterial thrombogenesis" J Am Coll Cardiol, 34, 4:1208-15, 1999.www.cardiosource.com/library/journals/journal?sdid=4884

18. Kurl S et al. "Plasma vitamin C modifies the association betweenhypertension and risk of stroke." Stroke, 33, 6:1568-73, 2002. http://stroke.ahajournals.org/

19. Yokoyama T et al. "Serum vitamin C concentration was inverselyassociated with subsequent 20-year incidence of stroke in a Japanese ruralcommunity. The Shibata study." Stroke, 31, 10:2287-94, 2000. http://stroke.ahajournals.org/

20. Carr AC, Frei B. "Human neutraophils oxidize low-density lipoproteinby a hypochlorous acid-dependent mechanism: the role of vitamin C." BiolChem, 383, 3-4:627-36, 2002.

21. Sakuma N et al. "Ascorbic acid protects against peroxidativemodification of low-density lipoprotein, maintaining its recognition by LDLreceptors." J Nutr Sci Vitaminol (Tokyo), 47, 1:28-31, 2001.

22. Krajcovicova-Kudlackova M et al. "Homocysteine and vitamin C." BratislLek Listy, 103, 4-5:171-3, 2002.

23. Kelly PJ, Furie KL. "Management and prevention of stroke associatedwith elevated homocysteine." Curr Treat Options Cardiovasc Med, 4,5:363-71, 2002. www.treatment-options.com/cto_jrnl_home.cfm?JournalID=CM

24. Schnyder G et al. "Effect of homocysteine-lowering therapy withfolic acid, vitamin B(12) and vitamin B(6) on clinical outcome afterpercutaneous coronary intervention: the Swiss Heart study: a randomizedcontrolled trial." JAMA, 288, 8:973-9, 2002. www.jama.com

25. Stanger O et al. "Effects of folate treatment and homocysteinelowering on resistance vessel reactivity in atherosclerotic subjects." JPharmacol Exp Ther, 303, 1:158-62, 2002.

26. Woo KS et al. "Long-term improvement in homocysteine levels andarterial endothelial function after 1-year folic acid supplementation." AmJ Med, 112, 7:535-9, 2002. www-east.elsevier.com/ajm/menu.html

27. Tavintharan S, Kashyap ML. "The benefits of niacin inatherosclerosis." Curr Atheroscler Rep, 3, 1:74-82, 2001. www.current-reports.com/1523-3804/4/351

28. Kamanna VS, Kashyap ML. "Mechanism of action of niacin onlipoprotein metabolism." Curr Atheroscler Rep, 2, 1:36-46, 2000. www.current-reports.com/1523-3804/4/351

29. Kuvin JT et al. "A novel mechanism for the beneficial vasculareffects of high-density lipoprotein cholesterol: enhanced vasorelaxation andincreased endothelial nitric oxide synthase expression." Am Heart J,144, 1:165-72, 2002. www2.us.elsevierhealth.com/scripts/om.dll/

30. McCarty MF. "Inhibition of acetyl-CoA carboxylase by cystamine maymediate the hypotriglyceridemic activity of pantethine." Med Hypotheses,56, 3:314-7, 2001. www.harcourt-international.com/journals/mehy

31. Suter PM, Sierro C, Vetter W. "Nutritional factors in the control ofblood pressure and hypertension." Nutr Clin Care, 5, 1:9-19, 2002. www.blackwell-science.com/~cgilib/bsinc.bin?Journal=clinical

32. Chakraborti S et al. "Protective role of magnesium in cardiovasculardisease: a review." Mol Cell Biochem, 238, 1-2:163-79, 2002. www.wkap.nl

33. Touyz RM et al. "Effects of low dietary magnesium intake ondevelopment of hypertension in stroke-prone spontaneously hypertensive rats:role of reactive oxygen species." Hypertens, 20, 11:2221-32, 2002. http://hyper.ahajournals.org/

34. Mussoni L et al. "Magnesium inhibits arterial thrombi after vascularinjury in rat: in vivo impairment of coagulation." Thromb Haemost,86, 5:1292-5, 2001. www.schattauer.com/engstart.asp

35. Kang BP, Mehta U, Bansal MP. "Selenium supplementation protects fromhigh fat diet-induced atherogensis in rats: role of mitogen stimulatedlymphocytes and macrophage NO production." Indian J Exp Biol, 39,8:79-7, 2001. http://bioline.bdt.org.br/ie

36. Prabhu KS et al. "Selenium deficiency increases the expression ofinducible nitric oxide synthase in RAW 264.7 macrophages: role of nuclearfactor-kappaB in up-regulation." Biochem J, 366, 1:203-9, 2002. www.biochemj.org

37. Mehta U et al. "Studies of apoptosis and bcl-2 in experimentalatherosclerosis in rabbit and influence of selenium supplementation." GenPhysiol Biophys, 21, 1:15-29, 2002.

38. Kaikkonen J et al. "Coenzyme Q10: absorption, antioxidantiveproperties, determinants and plasma levels." Free Radic Res, 36,4:389-97, 2002. www.tandf.co.uk/journals

39. Singh RB et al. "Effect of coenzyme Q10 on experimentalatherosclerosis and chemical composition and quality of atheroma inrabbits." Atherosclerosis, 148, 2:275-82, 2000. www.elsevier.com/locate/inca/522790

40. Thomas SR et al. "Dietary cosupplementation with vitamin E andcoenzyme Q10 inhibits atherosclerosis in apolipoprotein E gene knockoutmice." Arterioscler Thromb Vasc Biol, 21, 4:585-93, 2001. http://atvb.ahajournals.org/

41. Witting PK et al. "Anti-atherogenic effect of coenzyme Q10 inapolipoprotein E gene knockout mice." Free Radic Biol Med, 29,3-4:295-305, 2000. www.elsevier.com/locate/freeradbiomed

42. Jeejeebhoy F et al. "Nutritional supplementation with MyoViverepletes essential cardiac myocyte nutrients and reduces left ventricular sizein patients with left ventricular dysfunction." Am Heart J, 143,6:1092-100, 2002. www2.us.elsevierhealth.com/scripts/om.dll/

43. Sole MJ, Jeejeebhoy KN. "Conditioned nutritional requirements:therapeutic relevance to heart failure." Herz, 27, 2:174-8, 2002. http://link.springer.de/link/service/journals/00059/

44. Retter AS. "Carnitine and its role in cardiovascular disease." HeartDis, 1, 2:108-13, 1999. www.heartdiseasej.com

45. Vescovo G et al. "L-carnitine: a potential treatment for blockingapoptosis and preventing skeletal muscle myopathy in heart failure." AmJ Physiol Cell Physiol, 283, 3:C802-10, 2002. http://ajpcell.physiology.org/

46. Martin MA et al. "Myocardial carnitine and carnitinepalmitoyltransferase deficiencies in patients with severe heart failure." BiochimBiophys Acta, 1502, 3:330-6, 2000.

47. Rizos I. "Three-year survival of patients with heart failure causedby dilated cardiomyopathy and L-carnitine administration." Am Heart J,139, 2 pt. 3:S120-3, 2000. www2.us.elsevierhealth.com/scripts/om.dll/

48. Dayanandan A, Kumar P, Panneerselvam C. "Protective role of L-carnitineon liver and heart lipid peroxidation in atherosclerotic rats." J NutrBiochem, 12, 5:254-7, 2001. www.elsevier.com/locate/jnutbio

49. Sayed-Ahmed MM et al. "L-carnitine prevents the progression ofatherosclerotic lesions in hypercholesterolaemic rabbits." Pharmacol Res,44, 3:235-42, 2001. www.academicpress.com/pharmres

50. Kris-Etherton PM et al. "AHA Scientific Statement: Fish consumption,fish oil, Omega-3 fatty acids and cardiovascular disease." Circulation,106, 21:2747-57, 2002. http://circ.ahajournals.org/

51. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardio."Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin Eafter myocardial infarction: results of the GISSI-Prevenzione trial." Lancet,354, 9177:447-55, 1999. www.thelancet.com

52. Albert CM et al. "Blood levels of long-chain n-3 fatty acids and therisk of sudden death." NEJM, 346, 15:1113-8, 2002. http://content.nejm.org

53. Hu FB et al. "Fish and omega-3 fatty acid intake and risk ofcoronary heart disease in women." JAMA, 287, 14:1815-21, 2002. www.jama.com

54. Lichtenstein AH. "Plant sterols and blood lipid levels." CurrOpin Clin Nutr Metab Care, 5, 2:147-52, 2002. www.co-clinicalnutrition.com

55. Hayes KC et al. "Free phytosterols effectively reduce plasma andliver cholesterol in gerbils fed cholesterol." J Nutr, 132:1983-8,2002. www.nutrition.org

56. Vaskonen T et al. "Supplementation of plant sterols and mineralsbenefits obese Zucker rats fed an atherogenic diet." J Nutr, 132,2:231-7, 2002. www.nutrition.org

57. Awad AB, Smith AJ, Fink CS. "Plant sterols regulate rat vascularsmooth muscle cell growth and prostacyclin release in culture." ProstaglandinsLeukot Essent Fatty Acids, 64, 6:323-30, 2001. www.harcourt-international.com/journals/plef/

58. Kanner J, Lapidot T. "The stomach as a bioreactor: dietary lipidperoxidation in the gastric fluid and the effects of plant-derivedantioxidants." Free Radic Biol Med, 31, 11:1388-95, 2001. www.elsevier.com/locate/freeradbiomed

59. Folts JD. "Potential health benefits from the flavonoids in grapeproducts on vascular disease." Adv Exp Med Biol, 505:95-111, 2002.

60. Vinson JA, Proch J, Bose P. "MegaNatural Gold Grapeseed Extract:in vitro antioxidant and in vivo human supplementation studies." J MedicFood, 4, 1:17-26, 2001.

61. Vinson JA. "The synergism between grape seed extract and vitamins Cand E." 219th American Chemical Society National Meeting, San Francisco,March 26-30, 2000.

62. Preuss HG et al. "Effects of niacin-bound chromium and grape seedproathocyanidin extract on the lipid profile of hypercholesterolemic subjects: apilot study." J Med, 31, 5-6:227-46, 2000.

63. Brito P, Almeida LM, Dinis TC. "The interaction of resveratrol withferrylmyoglobin and peroxynitrite; protection against LDL oxidation." FreeRadic Res, 36, 6:621-31, 2002. www.tandf.co.uk/journals

64. Aviram M, Fuhrman B. "Wine flavonoids protect against LDL oxidationand atherosclerosis." Ann NY Acad Sci, 957:146-61, 2002. www.annalsnyas.org

65. Leikert JF et al. "Red wine polyphenols enhance endothelial nitricoxide synthase expression and subsequent nitric oxide release from endothelialcells." Circulation, 106, 13:1614-7, 2002. http://circ.ahajournals.org/

66. Geleijnse JM et al. "Inverse association of tea and flavonoidintakes with incident myocardial infarction: the Rotterdam Study." Am JClin Nutr, 75, 5:880-6, 2002. www.ajcn.org

67. Peters U, Poole C, Arab L. "Does tea affect cardiovascular disease?A meta-analysis." Am J Epidemiol, 154:495-503, 2001. www.aje.oupjournals.org

68. Sasazuki S et al. "Relation between green tea consumption and theseverity of coronary atherosclerosis among Japanese men and women." AnnEpidemiol, 10, 401-8, 2000. www.medicinedirect.com/journal/journal?sdid=4964

69. Rohdewald P. "A review of the French maritime pine bark extract (Pycnogenol),a herbal medication with a diverse clinical pharmacology." Int J ClinPharmacol Ther, 40, 4:158-68, 2002.

70. Araghi-Niknam M et al. "Pine bark extract reduces plateletaggregation." Integr Med, 2, 2:73-7, 2000. www.sciencedirect.com/science

71. Hosseini S et al. "A randomized, double blind, placebo controlled,prospective, 16-week crossover study to determine the role of Pycnogenol inmodifying blood pressure in mildly hypertensive patients." Nutr Res,21, 9:67-76, 2001. www.elsevier.com/locate/issn/02715317

72. Devaraj S et al. "Supplementation with a pine bark extract rich inpolyphenols increases plasma anitoxidant capacity and alters the plasmalipoprotein profile." Lipids, 37, 10:931-4, 2002. www.aocs.org

73. Polidori MC et al. "Plasma carotenoid and malondialdehyde levels inischemic stroke patients: relationship to early outcome." Free Radic Res,36, 3:265-8, 2002. www.tandf.co.uk/journals

74. Dwyer JH et al. "Oxygenated carotenoid lutein and progression ofearly atherosclerosis: the Los Angeles atherosclerosis study." Circulation,103, 24:2922-7, 2001. http://circ.ahajournals.org/

75. Rissanen T et al. "Lycopene, atherosclerosis and coronary heartdisease." Exp Biol Med (Maywood), 227, 10:900-7, 2002.

76. Gianetti J et al. "Inverse association between carotid intima-mediathickness and the antioxidant lycopene in atherosclerosis." Am Heart J,143, 3:467-74, 2002. www2.us.elsevierhealth.com/scripts/om.dll/

77. Rao AV. "Lycopene, tomatoes and the prevention of coronary heartdisease." Exp Biol Med (Maywood), 227, 10:908-13, 2002.

78. Takeoka GR et al. "Processing effects on lycopene content andantioxidant activity of tomatoes." J Agric Food Chem, 49, 8:3713-7,2001. http://pubs.acs.org/journals/jafcau

79. Fuhrman B et al. "Lycopene synergistically inhibits LDL oxidation incombination with vitamin E, glabridin, rosmarinic acid, carnosic acid orgarlic." Antioxid Redox Signal, 2, 3:491-506, 2000. http://matilde.ingentaselect.com/

80. Tonstad S, Smerud K, Hoie L. "A comparison of the effects of 2 dosesof soy protein or casein on serum lipids, serum lipoproteins, and plasma totalhomocysteine in hypercholesterolemic subjects." Am J Clin Nutr, 76,1:78-84, 2002. www.ajcn.org

81. Ridges L et al. "Cholesterol lowering benefits of soy and linseedenriched foods." Asia Pac J Clin Nutr, 10, 3:204-11, 2001. www.blackwellpublishing.com/journal.asp?ref=0964-7058

82. Lichtenstein AH et al. "Lipoprotein response to diets high in soy oranimal protein with and without isoflavones in moderately hypercholesterolemicsubjects." Arterioscler Thromb Vasc Biol, 22, 11:1852-8, 2002. http://atvb.ahajournals.org/

83. Clarkson B. "Soy, soy phytoestrogens and cardiovasculardisease." J Nutr, 132, 3:566S-569S, 2002. www.nutrition.org

84. Clarkson TB. "Soy, soy phytoestrogens and cardiovasculardisease." J Nutr, 132, 3:566S-9S, 2002. www.nutrition.org

85. van der Schouw YT et al. "Higher usual dietary intake ofphytoestrogens is associated with lower aortic stiffness in postmenopausalwomen." Arterioscler Thromb Vasc Biol, 22, 8:1316-22, 2002. http://atvb.ahajournals.org/

86. Rahman K. "Historical perspective on garlic and cardiovasculardisease." J Nutr, 131, 3s:977S-9S, 2001. www.nutrition.org

87. Ackermann RT et al. "Garlic shows promise for improving somecardiovascular risk factors." Arch Intern Med, 161, 6:813-24, 2001. http://archinte.ama-assn.org

88. Stevinson C, Pittler MH, Ernst E. "Garlic for treatinghypercholesterolemia. A meta-analysis of randomized clinical trials." AnnIntern Med, 133, 6:420-9, 2000. www.annals.org

89. Preuss HG et al. "Wild garlic has a greater effect than regulargarlic on blood pressure and blood chemistries of rats." Int UrolNephrol, 32, 4:525-30, 2001. www.kluweronline.com/issn/0301-1623

90. Durak I et al. "Effects of garlic extract on oxidant/antioxidantstatus and atherosclerotic plaque formation in rabbit aorta." Nutr MetabCardiovasc Dis, 12, 3:141-7, 2002. www.medikal.it/index_en.htm

91. Rahman K, Billington D. "Dietary supplementation with aged garlicextract inhibits ADP-induced platelet aggregation in humans." J Nutr,130, 11:2662-5, 2000. www.nutrition.org

92. Borek C. "Antioxidant health effects of aged garlic extract." JNutr, 131, 3s:1010S-5S, 2001. www.nutrition.org

93. Walker AF et al. "Promising hypotensive effect of hawthorn extract:a randomized double-blind pilot study of mild, essential hypertension." PhytotherRes, 16, 1:48-54, 2002. www.interscience.wiley.com/jpages/0951-418X

94. Fuhrman B et al. "Antiatherosclerotic effects of licorice extractsupplementation on hypercholesterolemic patients: increased resistance of LDL toatherogenic modifications, reduced plasma lipid levels and decreased systolicblood pressure." Nutrition, 18:268-73, 2002. www.elsevier.com/locate/nut

95. Ma YX, Chen SY. Zhong Xi Yi He Za Zhi, 9:335-7, 1989.